Rezera IPO: A Phase 3 Bet with a Financing Deadline

Rezera IPO: A Phase 3 Bet with a Financing Deadline

SERRARI GROUP / ANALYST DESK — US BIOTECH | PROPOSED NASDAQ IPO

Ruvonoflast offers clinical upside. The IPO also addresses a near-term funding constraint; drug approval and market value remain contingent.

$200m — Gross raise at $12 midpoint

$3.9m — Cash at 30 June 2026

2028 — Target Phase 3 topline readout

16.67m proposed shares | $11–$13 price range | RZRA (proposed)

RESEARCH CUT-OFF: 09 NOVEMBER 2026 | SCENARIOS ARE ILLUSTRATIVE

Executive take

The deal is both an NLRP3 development wager and a recapitalisation event. [F1–F3]

What is being offered

The preliminary offer covers 16.67 million new common shares at $11–$13 each. At the $12 midpoint, gross proceeds are approximately $200 million; net proceeds are estimated near $181 million before any underwriter option.

Why the IPO now

The company held only $3.9 million in cash on 30 June. Subsequent July equity and debt financing gave it an operating runway into January 2027, according to its filing. Access to public capital is central to the Phase 3 plan.

Clinical investment thesis

Ruvonoflast is an oral NLRP3 inhibitor being advanced toward a Phase 3 peripheral artery disease study planned for the first half of 2027, with expected 2028 topline data. Clinical success is not assured.

Analyst assessment

A strategic GSK indication offers external validation but is non-binding. The central uncertainty is whether efficacy, safety and trial execution justify a market value well above the company’s pre-IPO cash resources.

Deal anatomy: price, dilution and proceeds

A 12 November listing is an indicative market-calendar date, not proof of pricing or completed trading. [F2, F3]

Proposed public instrument

Voting common shares, proposed Nasdaq Global Market symbol RZRA. This is a conventional issuer equity IPO, not an ADS or units-and-warrants offering.

Investor supply

16,666,667 primary shares plus an option for underwriters to buy up to 2.5 million additional shares. Base case post-offer shares outstanding: approximately 20.78 million.

Gross range and issuer cash

$183.3 million to $216.7 million gross at $11–$13, with $200 million at midpoint. Prospectus midpoint net proceeds of approximately $181 million reflect fees and expenses.

Potential strategic participation

GSK indicated interest in purchasing up to approximately $25 million of IPO shares, about 10% of base post-IPO shares at midpoint. An indication is not a binding commitment.

Business model: pre-revenue therapeutic assets

There are no approved medicines or drug-sale revenues. Value resides in clinical and regulatory optionality. [F1, F2]

Lead programme: ruvonoflast

A proprietary oral NLRP3 inhibitor directed at inflammation-related disease, with Phase 2 experience. The planned Phase 3 PAD trial is the major economic catalyst.

Secondary programme: trabzanoflast

A brain-penetrant NLRP3 inhibitor that has completed a Phase 1 study. Development remains earlier stage and requires additional proof-of-concept funding.

Commercialisation path

Successful Phase 3 results would still need regulatory assessment, manufacturing readiness, payer access and commercial execution. The IPO price cannot be treated as a valuation of realised product sales.

Competitive moat and limits

Patent rights, molecule characteristics and clinical evidence may create durable value, but mechanism-level promise does not establish superiority. Competitor data, adverse events and development delays can reset expectations.

Historical cash burn and losses

Losses accelerated as development spending expanded; balance-sheet cash is a snapshot, not a runway measure. [F1, F2]

Reported net losses (US$ millions)

FY2024: 25 · FY2025: 42 · H1 2025: 14 · H1 2026: 26

Observed cash use

Six-month operating cash outflow increased from approximately $14.6 million in H1 2025 to $17.9 million in H1 2026. Cash at 30 June 2026 was $3.85 million.

Interpretation

A simple cash-to-burn ratio based only on the June balance understates subsequent financing. The issuer disclosed a July $15.2 million equity financing and $15 million term borrowing, with runway into January 2027.

Source: issuer prospectus; H1 values cover six months only and must not be mixed with full-year losses.

Why the financing need matters

The immediate capital raise funds a milestone; a product franchise remains further out. [F2]

Runway condition

Management expects cash from the IPO, existing resources and prior financing to carry the lead programme through expected Phase 3 topline data in 2028. This depends on trial scope and costs.

Second programme funding gap

The company says base offering proceeds are not expected to cover a full Phase 2 trabzanoflast proof-of-concept programme through topline data. Portfolio breadth remains capital-constrained.

Key sensitivity

Larger enrolment, slower site activation, manufacturing or safety follow-up requirements can increase burn. New equity, partnerships or debt may be necessary if the lead programme runs over budget.

Why shareholders care

A cash-funded catalyst can improve negotiating leverage, but the same transition increases near-term costs. Investors own a probability-weighted clinical outcome, not predictable operating earnings.

Implied valuation under the preliminary price range

Equity market value is an illustrative post-offering share-count calculation, not enterprise value. [F2]

Base post-offer equity value (US$ millions)

$11 low: 229 · $12 mid: 249 · $13 high: 270

Shares outstanding

20.776793 million base shares following the offering; the prospectus separately describes a 2.5 million-share underwriting option and other equity instruments.

Better valuation lens

Traditional P/E is not meaningful without earnings or product sales. Clinical milestone probability, peak-sales uncertainty, regulatory timing and future financing should drive scenario analysis.

Illustration: $228.5m / $249.3m / $270.1m post-offer equity values; excludes full dilution.

Post-offering ownership and dilution

Primary issuance increases capital available to the company while reweighting ownership. [F2]

New investor ownership

Base newly issued shares represent approximately 80.2% of the 20.78 million common shares shown in the prospectus post-IPO share table. This reflects the issuer’s specific recapitalisation structure.

Existing shareholder interests

Existing holders retain an estimated 4.11 million base common shares before giving effect to other non-voting conversion and incentive instruments. Examine the complete capitalisation tables.

Underwriter option effect

Full option exercise adds 2.5 million common shares, increasing base share count to approximately 23.28 million; proceeds also rise. Compare fully diluted equity value rather than headline share counts alone.

Strategic investor caveat

GSK’s proposed allocation may meaningfully influence the post-IPO register, but the shares are not committed. Analyse the side-agreement rights separately from an implied endorsement of clinical success.

Use of proceeds: development sequence

Offering proceeds target an identifiable clinical readout rather than immediate revenue creation. [F2]

01 CAPITAL — Public-equity proceeds plus existing cash and prior financing.

→ 02 CLINICAL — Proposed Phase 3 PAD trial, sites, monitoring and patient data.

→ 03 READOUT — Management targets topline results during 2028.

→ 04 OPTION — Regulatory pathway, partnering or further financing if results support progress.

Capital-efficiency test

Does the expected $181 million midpoint net raise provide adequate contingency for the planned study? Investors should monitor actual trial enrolment, contracted costs, and the pace of operating cash use.

Portfolio trade-off

Concentrating resources on ruvonoflast may raise the probability of reaching its principal readout, but pushes development of trabzanoflast behind a future financing or partnership decision.

Risk matrix: where loss can occur

Figure: Risk matrix — where loss can occur.

Transmission: from data to equity value

Why clinical, financial and market signals compound rather than act independently.

01 TRIAL — Recruitment speed, retention, efficacy and adverse events.

→ 02 COST — Clinical milestones determine operating expense and cash need.

→ 03 CAPITAL — New debt or equity depends on cash runway and sentiment.

→ 04 VALUE — Success probability and diluted shares drive per-share value.

Bullish mechanism

Timely enrolment and compelling Phase 3 efficacy could improve partnership options and reduce future financing discounts, supporting clinical franchise value.

Bearish mechanism

Safety concerns or a delayed readout may increase cash burn while reducing financing appetite, combining lower probability of success with a higher dilution burden.

Scenario map: what changes the thesis

Outcomes are conditional, not assigned numerical probabilities or targets.

Upside: differentiated proof

The proposed Phase 3 starts broadly on schedule and generates robust efficacy with manageable safety. Funding covers the milestone, strengthening optionality for regulatory engagement or a strategic transaction.

Central: funded but binary

The IPO closes near the midpoint and extends cash runway to the expected 2028 readout. Valuation remains volatile around recruitment milestones, data updates and industry risk appetite. Further capital may be needed later.

Downside: delay or failure

The Phase 3 slips, costs overrun, or efficacy/safety disappoints. Cash burn persists, partnership optionality weakens, and additional equity is raised at less attractive terms. Existing holders experience devaluation.

Scenarios describe conditional paths, not probability-weighted price targets or investment recommendations.

Pre-IPO and post-listing dashboard

Four live checks can distinguish a good company from an attractive security at a specific price. [F1–F3]

1. Final prospectus

Confirm final price, gross proceeds, underwriting option, lock-ups, voting/non-voting conversions and any changes to GSK commitments.

2. Clinical timetable

Follow site activation, patient numbers, protocol changes and the beginning of Phase 3 PAD enrolment. Calendar slippage is often financially meaningful before a readout.

3. Quarterly liquidity

Track cash, term-loan terms, R&D burn, obligations and follow-on financing language; calculate runway using current spending rather than the June 2026 balance alone.

4. Market and peer signals

Compare newly public clinical-stage peers by cash runway and development progress, not by conventional P/E. Monitor sector risk appetite after any biotech funding shock.

Investment assessment: programme value vs funding risk

A credible milestone financing does not remove the binary nature of development-stage biotechnology.

$181m — Estimated midpoint net proceeds

$249m — Implied base equity value at $12

2028 — Expected lead-programme readout

Serrari Analyst Desk conclusion

Rezera presents a focused clinical-stage opportunity: the IPO could fund ruvonoflast to a high-value Phase 3 milestone, but it does not validate regulatory approval or future commercial revenue. The latest preliminary terms support an investment case built around clinical execution, balance-sheet duration and fully diluted valuation. Investors should not confuse GSK’s non-binding indication with a guaranteed strategic outcome. Assessment: high-upside, high-binary-risk issuer; price discipline and monitoring of trial milestones are essential.

Sources, method and release checks

SERRARI GROUP | ANALYST DESK | 09 NOVEMBER 2026

Evidence register

F1 — Rezera initial S-1, 21 October 2026 — Clinical programmes, financial statements and risks.

F2 — Rezera amended S-1/A, 9 November 2026 — Updated offering terms, GSK indication and proceeds.

F3 — IPO schedule, 9 November 2026 — Indicative 12 November trading calendar; not definitive.

F4 — Sector offering coverage, 5 November 2026 — Independent check on price range, positioning and bookrunners.

Methodology and interpretation

The S-1/A is a preliminary, non-effective offering document as of this research cut-off; dates can change. Revenue is not projected because the issuer has not generated drug-sale revenue. Gross value at low/mid/high offer prices equals 16,666,667 shares multiplied by $11/$12/$13. Implied post-issue equity value uses 20,776,793 post-offering shares, excluding option/warrant complexity unless otherwise stated. Company-reported losses and June cash balances refer to different periods and do not constitute an annualised loss forecast.

Investment-risk notice

For financial research, market education and decision support only. Not an offer, solicitation, personalised investment recommendation or assurance of listing. Preliminary prospectus terms may change. Underwriting, warrants, contingencies, taxes and subsequent capital actions may alter implied values and ownership. Perform independent due diligence and consult the final prospectus before investing.

Publication QA

Figures checked against issuer filings as cited; market calendars are indicative; SEC documents do not establish an exchange trading date until the relevant conditions are fulfilled. All analyst sensitivity calculations are identified as illustrative.